Arbutus Biopharma Logo
Tekmira Provides Update on Licensed Product Candidate, Marqibo(R)
March 22, 2012 01:17 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 22, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed...
Arbutus Biopharma Logo
Tekmira Provides Update on Progress in USPTO Patent Interference Proceedings
March 15, 2012 00:50 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 15, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that...
Arbutus Biopharma Logo
Tekmira Files Motion to Dismiss in Patent Infringement Suit
March 06, 2012 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 6, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that...
Arbutus Biopharma Logo
Tekmira Expands Product Pipeline With RNAi Therapeutic for the Treatment of Alcohol Dependence
March 01, 2012 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 1, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira Updates Financial Guidance: Cash Runway Further Extended Into Second Half of 2013
February 29, 2012 23:57 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 29, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, has updated its...
Arbutus Biopharma Logo
Tekmira Announces USPTO Issuance of Key Patents Broadly Covering LNP Formulations and Mitigation of Immune Stimulation
February 09, 2012 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, B.C., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that the...
Arbutus Biopharma Logo
Tekmira Announces Initiation of TKM-Ebola Phase 1 Clinical Trial
February 08, 2012 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 8, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Arbutus Biopharma Logo
Tekmira Provides Periodic Update to Litigation
January 17, 2012 16:32 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that...
Arbutus Biopharma Logo
Tekmira Granted an Injunction Against Certain Individuals From AlCana Technologies by the Supreme Court of British Columbia
January 10, 2012 16:30 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 10, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed today...
Arbutus Biopharma Logo
Tekmira's LNP Technology Enables Alnylam's Positive ALN-PCS Clinical Data
January 04, 2012 16:03 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 4, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...